Skip to main content
All lobbying filings

ALPINE GROUP PARTNERS, LLC.

Lobbying for ULTRAGENYX PHARMACEUTICAL INC. · Biopharma company developing treatments for rare and ultra-rare diseases.

 Filing 2nd Quarter - Report
Reporting period
2nd Quarter 2026
Apr 1 - June 30 · Posted Jul 20, 2026
Income
$60,000.00
What the client paid this registrant for the period.
Client based in
California

Official filing document

 Lobbyists on this filing 3
  • ERIN MENDELSOHN
    Previously held: LD, Rep. Anna Eshoo; Congressional Liaison - FDA
  • KEENAN AUSTIN REED
    Previously held: Chief of Staff, Rep. Donald McEachin; Deputy Chief of Staff, Rep. Frederica S. Wilson
  • SHAYNE WOODS
    Previously held: Senior Legislative Assistant, Sen. Tim Scott; Senior Policy Advisor, Rep. Gus Bilirakis

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 2
  • HOUSE OF REPRESENTATIVES
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Lobbying activity 3
Health Issues

Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases like Sanfilippo syndrome Type A, Duchenne Muscular Dystrophy (DMD), and Metachromatic Leukodystrophy (MLD)

Government Issues

Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases like Sanfilippo syndrome Type A, Duchenne Muscular Dystrophy (DMD), and Metachromatic Leukodystrophy (MLD)

Medical/Disease Research/Clinical Labs

Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases like Sanfilippo syndrome Type A, Duchenne Muscular Dystrophy (DMD), and Metachromatic Leukodystrophy (MLD)

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem